Analytical Data
-
Gene name
CDK1-CCNE1
- Application
-
Alternative Names
CDC2; CDC28A; CDK1; CDC28-A; CDKN1; P34CDC2; p34 protein kinase; Cell Division Control Protein 2 Homolog; Cell Division Cycle 2,G1 To S And G2 To M
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P11440
-
Expression Region
Gly13~Met297
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK1 (Cyclin-Dependent Kinase 1) and CCNE1 (Cyclin E1) are pivotal proteins in cell cycle regulation, particularly in the transition from the G1 phase to the S phase. CDK1, when activated by its cyclin partner, plays a crucial role in driving cells through mitosis, while CCNE1 is essential for the G1/S transition, regulating the activity of CDK2. Aberrant expression or dysregulation of these proteins is associated with various cancers, making them potential targets for therapeutic intervention. Research into the recombinant forms of CDK1 and CCNE1 enables a deeper understanding of their molecular mechanisms and interactions, facilitating the development of inhibitors that could disrupt their activity in tumorigenesis. Furthermore, studying the structural and functional properties of CDK1-CCNE1 complexes through recombinant protein techniques can provide insights into their roles in cell cycle progression and highlight the implications of their dysregulation in cancer biology. This research underscores the importance of CDK1 and CCNE1 not only in fundamental cell cycle control but also as potential biomarkers and therapeutic targets in cancer treatment strategies.
